NCT00828191View on ClinicalTrials.gov

Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

February 29, 2012

Conditions
In Vitro Fertilization
Interventions
DRUG

Progesterone

25 mg, once a day, SC

DRUG

Progesterone

100 mg, twice a day, vaginally

Trial Locations (8)

32804

Center for Reproductive Medicine, Orlando

76022

Center for Assisted Reproduction, Bedford

83702

Idaho Center for Reproductive Medicine, Boise

90277

Reproductive Partners Medical Group, Inc., Redondo Beach

91360

Fertility and Surgical Associates of California, Thousand Oaks

94305

Stanford University Medical Center, Stanford

95124

Fertility Physicians of Northern California, San Jose

98109

Seattle Reproductive Medicine, Seattle

Sponsors
All Listed Sponsors
lead

IBSA Institut Biochimique SA

INDUSTRY